Background. The circumferential resection margin (CRM) is highly prognostic for local recurrence in rectal cancer surgery without neoadjuvant treatment. However, its significance in the setting of long-course neoadjuvant chemoradiotherapy (nCRT) is not well defined. Methods. Review of a single institution's prospectively maintained database from 1998 to 2007 identified 563 patients with locally advanced rectal cancer (T3/T4 and/or N1) receiving nCRT, followed after 6 weeks by total mesorectal excision (TME). Kaplan-Meier, Cox regression, and competing risk analysis were performed. Results. The authors noted that 75 % of all patients had stage III disease as determined by endorectal ultrasound (ERUS) and/or magnetic resonance imaging (MRI). With median follow-up of 39 months after resection, local and distant relapse were noted in 12 (2.1 %) and 98 (17.4 %) patients, respectively. On competing risk analysis, the optimal cutoff point of CRM was 1 mm for local recurrence and 2 mm for distant metastasis. Factors independently associated with local recurrence included CRM B1 mm, and highgrade tumor (p = 0.012 and 0.007, respectively). CRM B2 mm, as well as pathological, nodal, and overall tumor stage are also significant independent risk factors for distant metastasis (p = 0.025, 0.010, and\0.001, respectively). Conclusion. In this dataset of locally advanced rectal cancer treated with nCRT followed by TME, CRM B1 mm is an independent risk factor for local recurrence and is considered a positive margin. CRM B2 mm was associated with distant recurrence, independent of pathological tumor and nodal stage.
is an independent risk factor for local recurrence and is considered a positive margin. CRM B2 mm was associated with distant recurrence, independent of pathological tumor and nodal stage.
At the time of rectal cancer surgery, a positive circumferential radial margin (CRM) indicates incomplete resection and is associated with high rates of local and distant recurrence. [1] [2] [3] [4] This has been well documented in studies that do not use neoadjuvant therapy. When delivered in 25-28 fractions over 5-6 weeks, chemoradiotherapy induces tumor downsizing and downstaging, which facilitates complete resection. 5, 6 The optimal radial margin has not been well defined. For instance, in a comprehensive review of the literature, Nagtegaal and Quirke report positive CRM is associated with local recurrence; however, the definition of CRM varied between studies. 7 The aim of this study was to further define the relationship between CRM and local and distant recurrence in the setting of long-course neoadjuvant chemoradiotherapy.
MATERIALS AND METHODS

Study Population
Following approval of this study by the Institutional Review Board of Memorial Sloan-Kettering Cancer Center (MSKCC), we performed a review of a prospectively maintained institutional database from 1998 to 2007. We identified 563 patients diagnosed with locally advanced rectal cancer (T3/4 or N1) by endorectal ultrasonography (ERUS) and/or magnetic resonance imaging (MRI). All of these patients received an infusional fluorouracil chemotherapy regimen concurrent with radiotherapy (50.4 Gy in 28 fractions), followed by a 6-week break. The break was followed by resection, performed according to the standard technique of total mesorectal excision. Demographic data, clinical characteristics, operative procedure, and histopathology were examined.
Pathologic Assessment
Specimens were inked and fixed. The entire tumor was sectioned perpendicularly to include the radial margin. The CRM was measured as the distance from the deepest part of the tumor in the inked soft tissue edge.
Pathologists reported the tumor response from neoadjuvant treatment by measuring the proportion of residual viable tumor mass replaced by the amount of fibrosis. Percent response was defined by the percent of lesion composed of fibrous or fibroinflammatory tissues in the primary lesion. The complete pathological response was defined as complete regression of the tumor, by means of no disease left in the specimen.
Statistical Analysis
The Pearson v 2 -test for binary parameters was used to compare demographic data between groups. Analysis of CRM as a continuous variable was performed to identify the optimal cutoff point(s) associated with local recurrence and distant metastasis. Univariate analysis of recurrencefree survival was calculated using the Kaplan-Meier procedure-limit method and reported as median survival and estimated 5-year survival. Multivariate analysis was performed using the Cox proportional hazards regression method. A p value B0.05 was considered statistically significant.
RESULTS
A total of 563 patients with locally advanced rectal cancer were included in this study. Median age at diagnosis was 60 years (range, 17-88 years). The majority of patients were male (59 %). Also, 477 patients (85 %) underwent low anterior resection (LAR), and 85 (15 %) underwent abdominoperineal resection (APR). Based on ERUS and/or MRI, 75 % were clinical stage III and 25 % were clinical stage II. Of all patients, 20 % were found to have pathological complete response after multimodality treatment. The median follow-up was 39 months with an interquartile range from 27 to 55 months. There were 12 patients (2 %) who developed local recurrence and 98 (17 %) who developed distant metastasis within the follow-up period. The median interval between completion of neoadjuvant treatment and surgery was 48 days.
Optimal CRM Cutoff Point
In an attempt to identify the most prognostic cutoff point, CRM was analyzed as a continuous variable (Fig. 1) . Unfortunately, no clear inflection point was noted for either local or distant recurrence. Competing risk analysis was then used to determine the association of CRM with local and distant recurrence. For local recurrence, creation of cohorts based on CRM B1 and[1 mm (1-mm cutoff point) resulted in the greatest separation of recurrence curves, compared with 2 mm and 4 mm (Fig. 2a) . A total of 20 patients had CRM B1 mm (Table 1) compared with those undergoing low anterior resection (LAR) (10.3 vs 3.6 %, p = 0.016). In contrast, when analyzing distant recurrence, a cutoff point of 2 mm created the greatest separation of survival curves (Fig. 2b) .
Local Recurrence
Univariate analyses demonstrated that low rectal cancer (B5 cm from the anal verge; p \ 0.001), advanced pathological staging (ypT3-4; p \ 0.02), high-grade tumor (poorly differentiated to undifferentiated; p \ 0.005), and CRM B1 mm (p \ 0.001) were associated with local recurrence ( Table 2 ). The 5-year local recurrence-free survivals were 66 and 98 % in CRM B1 and [1 mm, respectively. Multivariate analysis confirmed that CRM and tumor grade are independent prognostic factors for local recurrence (Table 3) .
Distant Metastasis
Univariate analysis demonstrated that low rectal cancer (p \ 0.003), advanced pathological staging (p \ 0.001), high-grade tumor biology (p \ 0.004), partial tumor response (p \ 0.001), pathological nodal (ypN) disease (p \ 0.001), and CRM B2 mm (p \ 0.001) were significantly associated with distant recurrence (Table 2 ). Multivariable analysis confirmed that CRM, as well as pathological tumor (ypT) and nodal (ypN) stage, were independent prognostic factors for distant metastasis (Table 3) . (Fig. 3a) . We identified no association between CRM and primary tumor response to chemoradiotherapy (Fig. 3b) .
DISCUSSION
The strong association between CRM and local recurrence was clearly demonstrated in 1986 by Quirke et al. in a series of patients undergoing rectal cancer surgery without neoadjuvant therapy. Local recurrence developed in 85 % of all patients (11 of 13) with a positive CRM (B1 mm), compared with 3 % of those with a clear margin (1 of 38).
1 These results were reproduced by several investigators, again in the setting of no preoperative therapy. 2, 3, 8, 9 The optimal cutoff for defining positive CRM is still debated, however, and some investigators propose 2 mm rather than 1 mm.
2,8 Nagtegaal et al. reported on a series of 656 rectal cancer patients undergoing rectal resection without neoadjuvant treatment. They found that patients with CRM B2 mm had a 16 % risk of local recurrence at 2 years, compared with 5.8 % risk for those patients with CRM [2 mm (p \ 0.001). The authors also noted that CRM B1 mm was associated with distant metastasis. 2 However, most of the literature defines a positive CRM as tumor within 1 mm of the cut surface, and this definition is currently endorsed by the NCCN Guidelines.
1-4,10,11
The prognostic significance of CRM status in the setting of neoadjuvant treatment is not as well defined, because the majority of studies excluded patients receiving neoadjuvant treatment. One might expect different results in patients treated neoadjuvantly, as long-course neoadjuvant chemoradiotherapy results in tumor downsizing and downstaging in a majority of cases. 5, 6 In a comprehensive review of the literature, Nagtegaal and Quirke 7 noted that CRM was a more powerful predictor of local recurrence in patients treated with neoadjuvant therapy (hazard ratio [HR] = 6.3; 95 % confidence interval [95 % CI], 3.7-16.7 in studies using neoadjuvant therapy vs HR = 2.0; 95 % CI, 1.4-2.9 in studies not using neoadjuvant therapy).
The current study evaluates the significance of CRM in a homogeneous cohort of locally advanced rectal cancer patients receiving standard long-course neoadjuvant chemoradiotherapy, followed by total mesorectal excision. The results suggest that CRM remains an independent prognostic factor for local recurrence. The 5-year local recurrence-free survival is significantly different in patients with CRM B1 mm than in patients with CRM [1 mm (66 vs 98 %, respectively, p \ 0.001). This result supports the current NCCN Guidelines.
Furthermore, CRM is also an independent prognostic factor for distant recurrence. Of note, while a wider CRM was associated with fewer recurrences, 2 mm appears to create the greatest separation of survival curves, indicating the optimal cutoff point compared with 4-and 1-mm margins. The 5-year distant recurrence-free survival is 41 % in CRM B2 mm and 78 % in CRM [2 mm (p = 0.001). One could hypothesize that those tumors that do threaten the mesorectal margin and do not regress with neoadjuvant therapy represent aggressive tumor biology. Although one may expect that tumors with greater response to chemoradiation will demonstrate more regression from the mesorectal fascia, we did not identify a relationship between CRM and response to chemoradiation (percent tumor regression or tumor regression grade). This may result from the fact that not all stage II and III tumors encroach upon the mesorectal fascia at presentation. Multivariate analysis further demonstrated that CRM and pathological staging are independent prognostic factors, whereas the treatment response is not a significant factor. This result is consistent with previously published data from our institution concluding that postoperative pathological tumor and nodal staging are more important prognostic factors than treatment response. 5 As demonstrated in our study, the association of CRM with distant recurrence is identified not only in the setting of neoadjuvant treatment but in the setting of no neoadjuvant treatment as well. 2, 9, 12, 13 The higher rate of positive CRM in patients undergoing APR versus LAR is again demonstrated in this study. This finding is consistent with the literature, which reports positive CRM in 15-30 %. 2, 8, 9, 14 Even with optimal cylindrical/extralevator resection, CRM positivity rates approach 15 %. 10, 15 The Polish study comparing shortcourse radiotherapy to long-course chemoradiotherapy noted a significant reduction in positive CRM in the longcourse chemoradiation cohort. 16 In this study, the rate of positive CRM was demonstrated in seven of 68 patients undergoing APR (10.3 %).
This study shares the limitations associated with any retrospective review. Although treatment protocols were standardized, there was some variability in the time from end of chemoradiation to surgery, which could affect CRM. Furthermore, the low rate of local recurrence can limit statistical analysis.
In conclusion, in the setting of neoadjuvant chemoradiotherapy, CRM B1 mm is considered to be a positive margin and remains a poor prognostic factor for local recurrence. CRM B2 mm is a prognostic factor for distant metastasis, independent of pathological tumor (T) and nodal (N) staging.
